June 1-4 | Vienna, Austria
June 1-4 | Vienna, Austria
June 1-4 | Vienna, Austria
June 1-4 | Vienna, Austria
June 1-4 | Vienna, Austria
My experience submitting a case report abstract
Sajal Patel
Presenting author, “Traumatic high flow priapism in a child – embolotherapy for effective management“
Why did you choose ET to submit your case report abstract?
Being a subspecialist conference, I feel ET provides a more intimate platform upon which to present my work where it will be seen by individuals with a specific interest in the expanding world of embolotherapy. As interventionalists in the UK, some of our practices differ from our mainland European counterparts and attending the conference would give me the chance to discuss the particulars of our case with the world class clinicians in attendance, as well as allow me to benefit from the educational opportunities provided by CIRSE.
Tell us a little bit about the case you submitted and why you chose it for your submission.
Paediatric cases can cause anxiety in adult trained interventionalists. This case in particular demonstrated a scenario that while not immediately life threatening, did have the potential to significantly impact the child’s quality of life. We felt that sharing the imaging findings and our multidisciplinary approach may help other clinicians to formulate their management plans should they come across a similar case. There are also many different embolisation approaches available in this clinical context, so we felt there was value in sharing our technique for their consideration.
Are there any special considerations to take into account when submitting a case report abstract?
While it may sometimes seem like there is no new thing under the sun, patient and case specific factors may provide a new angle for learning even in a condition which otherwise seems well reported on in the literature. Trust your instincts – if you found the journey interesting, others may feel the same.
Do you have any tips for physicians submitting an abstract for the first time?
While as interventionalists, the technical aspects of the procedure are important, above all, we are clinicians and the details of the case and the decision-making process can be just as valuable a learning point as the procedure itself.
Will you submit another abstract for ET 2024?
An abstract is currently in draft. I look forward to learning about new and evolving trends in embolotherapy and showcasing the work we do at our IR unit.
Gregor Scharf
Presenting author, “Embolization of a congenital intrahepatic portosystemic shunt“
Why did you choose ET to submit your case report abstract?
As the field of embolotherapy is very interesting and evolving quickly, I wanted to contribute to this field. Musculoskeletal embolotherapy is becoming more and more popular and I was eager to visit ET 2023 and expand my knowledge on this topic.
Tell us a little bit about the case you submitted and why you chose it for your submission.
The case I chose was the embolization of a congenital portosystemic shunt in a child. I liked this case a lot, because it is a rare disease, but treatment was straightforward and the normalized blood ammonia level visualized successful treatment clearly. Furthermore, I hoped to make paediatric IR more popular with this case.
Are there any special considerations to take into account when submitting a case report abstract?
The difficulty in submitting a case report abstract is to find a case which is special, but not too complex. Many special cases are very complicated, which makes it difficult to explain the case within the word limit.
Do you have any tips for physicians submitting an abstract for the first time?
First, think about your case. What makes it special? What do you want to tell the reader? Then, write as clearly and as concisely as possible. The word limit is quite short and I end up cutting my abstracts regularly.
Will you submit another abstract for ET 2024?
I definitely plan on submitting another abstract! I am curious about the latest developments in embolotherapy and I think Vienna is a beautiful choice for ET 2024.
Why did you choose ET to submit your case report abstract?
ET is an academic conference that brings together specialists about embolization. I submitted my work to ET because I wanted people at such an international conference to learn about this new treatment method used in Japan.
Tell us a little bit about the case you submitted and why you chose it for your submission.
The case I chose was “Novel inferior gluteal artery access for type 2 endoleak embolization enabling the successful access site hemostasis by manual compression”.
Direct puncture of the aneurysm or superior gluteal artery has been proposed as approach to internal iliac artery aneurysms after EVAR in which standard antegrade access is impossible. Although these approaches are useful, access site hemostasis can be problematic given the deep position and the lack of a bony structure against which manual compression can be applied. Our novel inferior gluteal artery access just above the acetabulum could provide a safe option, enabling manual compression hemostasis because of the bony structure. I submitted this case to let people know about inferior gluteal artery access.
Are there any special considerations to take into account when submitting a case report abstract?
It may not be easy to summarize complex procedure details within the character limit. In the abstract, I tried to keep it simple.
Do you have any tips for physicians submitting an abstract for the first time?
If you come up with a new and safe treatment method, please share it with us. I think ET will accept your abstract.
Will you submit another abstract for ET 2024?
I’m looking for cases worth reporting. I would like to submit it to ET2024.
Why did you choose ET to submit your educational abstract?
I chose ET as it is the most prestigious international conference pertaining to embolotherapy.
Tell us a little bit about the case you submitted and why you chose it for your submission.
The case I chose is about a 53-year-old male with Marfan’s syndrome, chronic recurrent respiratory infection and multiple previous open aortic surgeries and endovascular stenting presented with haemoptysis (~30 mls/day).
Initial imaging demonstrated findings of aortobronchial fistula connecting the bronchioles to the thrombosed aneurysm sac without an obvious graft defect. No active aortic bleeding was identified. Chronic hypervascular inflammatory consolidation adjacent to the aortobronchial fistula was deemed to be a contributory factor to the development of the fistula. We made the decision to proceed with pulmonary artery embolisation in view of the ongoing haemoptysis and reduce the inflammatory changes to prevent further worsening of the aortobronchial fistula. I wanted to share this case, as it highlights the importance of prevention of further worsening of the aortobronchial fistula from the adjacent chronic inflammatory changes in the lung as well as the availability of an embolisation solution over stent relining in a patient with previous complex aortic stenting.
Are there any special considerations to take into account when submitting a case report abstract?
Case report abstracts should be made succinct for ease of understanding, but also ensuring the core essence of the case is not lost.
Do you have any tips for physicians submitting an abstract for the first time?
Reach out to colleagues who have submitted to ET previously for guidance! If you have any queries, do not be afraid to reach out to the organising committee of ET, they have been very helpful to me on my own journey.
Will you submit another abstract for ET 2024?
I have the intention to submit and attend the upcoming ET 2024.